ClinicalTrials.gg
CompletedNCT00855959Updated Mar 11, 2011Results posted

Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients

A Phase 3 interventional study of Budesonide and Pulmicort Turbuhaler in Asthma, sponsored by AstraZeneca. Completed at 6 sites in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2011-03-11.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Non-randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 110 studies testing budesonide in Asthma — 6 open to participants now, 6 under way, 3 of them phase 3. Budesonide · Asthma.

Enrollment
56th of 108
108 · median 124
Started
2009
with 2 others
Phase 3
51 of 110
3 open now
Registered
61st of 110
by date
Lead sponsor
41 of 110
AstraZeneca

Among the 110 studies testing budesonide in Asthma, this one is the 56th largest by enrollment of the 108 interventional ones that give a count, is one of 3 that started in 2009, is one of 51 in phase 3, and was the 61st registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

6 of the 110 studies testing budesonide in Asthma are open now, in 5 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies testing budesonide in Asthma, or all of them as a file.
02

Study summary

The primary objective of the study is to show similarity of efficacy on Pulmicort Respules 1.0 mg/day or 2.0 mg/day for 6 weeks in the treatment period and the corresponding doses of Pulmicort Turbuhaler 400 μg/day or 800 μg/day for 4 weeks in the observation period in Japanese adult asthmatic patients with age of 16 years or older.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Pulmicort Respules
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of prior to any study specific procedures.
  • A minimum of 6 months documented history of asthma according to the JGL 2006 definition
  • Asthma patients under prescribed treatment with ICS at least 3 months before Visit 2.

Exclusion criteria

Exclusion Criteria:

  • Current or previous tobacco smokers with a history of >= 10 pack-years
  • Use of β-blockers including eye drops
  • respiratory infection affecting the asthma, as judged by the investigator(s) within 4 weeks prior to visit 2
  • Intake of oral, rectal or parenteral GCS within 4 weeks prior to Visit 2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    1

    Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily

    Drug: Budesonide

  • Experimental
    2

    Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose)

    Drug: Pulmicort Turbuhaler

Interventions

  • Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks

    Also known as: Pulmicort

  • Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler

06

What researchers measure

Primary outcomes

  1. Morning Peak Expiratory Flow (mPEF)

    Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

Secondary outcomes

  1. Evening Peak Expiratory Flow (ePEF)

    Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  2. Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)

    Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  3. Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)

    Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  4. Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)

    Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  5. Use of Rescue Medication (Daytime)

    Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  6. Use of Rescue Medication (Night-time)

    Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  7. Use of Rescue Medication (Total)

    Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  8. Night-time Awakenings Due to Asthma Symptoms

    Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  9. Forced Expiratory Volume in 1 Second (FEV 1.0)

    Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  10. Forced Vital Capacity (FVC)

    Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

    Time frame: 6 weeks

  11. Number of Participants With Adverse Events (AEs)

    Number of participants with AEs reported during the period on Pulmicort Respules

    Time frame: 6 weeks

07

Results

Posted Mar 11, 2011

Participant flow

Outpatients, male and female ≥ 16 years with stable asthma

Participant flow — Overall Study
MilestonePulmicort Turbuhaler and Pulmicort Respules
Started108
Patients who received pulmicort respules105
Completed99
Not completed9
Withdrew: Adverse event2
Withdrew: Lost to follow-up2
Withdrew: Withdrawal by subject3
Withdrew: Pregnancy1
Withdrew: Incorrect enrolment1

Outcome measures

PrimaryMorning Peak Expiratory Flow (mPEF)

Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · L/min
Morning Peak Expiratory Flow (mPEF)
L/minPulmicort Turbuhaler and Pulmicort Respules
Morning Peak Expiratory Flow (mPEF)3.3 ± 21.4
SecondaryEvening Peak Expiratory Flow (ePEF)

Change in evening peak expiratory flow (ePEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · L/min
Evening Peak Expiratory Flow (ePEF)
L/minPulmicort Turbuhaler and Pulmicort Respules
Evening Peak Expiratory Flow (ePEF)3.8 ± 18.1
SecondaryAsthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)

Change in Asthma symptom score (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · Scores on a scale
Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)
Scores on a scalePulmicort Turbuhaler and Pulmicort Respules
Asthma Symptom Score (Daytime); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)0.018 ± 0.198
SecondaryAsthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)

Change in Asthma symptom score (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · Scores on a scale
Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)
Scores on a scalePulmicort Turbuhaler and Pulmicort Respules
Asthma Symptom Score (Night-time); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)0.022 ± 0.185
SecondaryAsthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)

Change in Asthma symptom score (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · Scores on a scale
Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)
Scores on a scalePulmicort Turbuhaler and Pulmicort Respules
Asthma Symptom Score (Total); Score of 0-3 (0 = no Asthma Symptoms - 3 = Severe Symptoms)0.039 ± 0.346
SecondaryUse of Rescue Medication (Daytime)

Change in Use of rescue medication (Daytime) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · puffs
Use of Rescue Medication (Daytime)
puffsPulmicort Turbuhaler and Pulmicort Respules
Use of Rescue Medication (Daytime)0.017 ± 0.160
SecondaryUse of Rescue Medication (Night-time)

Change in Use of rescue medication (Night-time) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · puffs
Use of Rescue Medication (Night-time)
puffsPulmicort Turbuhaler and Pulmicort Respules
Use of Rescue Medication (Night-time)0.044 ± 0.220
SecondaryUse of Rescue Medication (Total)

Change in Use of rescue medication (Total) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · puffs
Use of Rescue Medication (Total)
puffsPulmicort Turbuhaler and Pulmicort Respules
Use of Rescue Medication (Total)0.061 ± 0.317
SecondaryNight-time Awakenings Due to Asthma Symptoms

Change in Night-time awakenings due to asthma symptoms from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · awakenings
Night-time Awakenings Due to Asthma Symptoms
awakeningsPulmicort Turbuhaler and Pulmicort Respules
Night-time Awakenings Due to Asthma Symptoms-0.004 ± 0.165
SecondaryForced Expiratory Volume in 1 Second (FEV 1.0)

Change in Forced Expiratory Volume in 1 second (FEV 1.0) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · L
Forced Expiratory Volume in 1 Second (FEV 1.0)
LPulmicort Turbuhaler and Pulmicort Respules
Forced Expiratory Volume in 1 Second (FEV 1.0)0.079 ± 0.244
SecondaryForced Vital Capacity (FVC)

Change in Forced Vital Capacity (FVC) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)

Time frame:
6 weeks
Reported as:
Mean · L
Forced Vital Capacity (FVC)
LPulmicort Turbuhaler and Pulmicort Respules
Forced Vital Capacity (FVC)0.105 ± 0.283
SecondaryNumber of Participants With Adverse Events (AEs)

Number of participants with AEs reported during the period on Pulmicort Respules

Time frame:
6 weeks
Reported as:
Number · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPulmicort Turbuhaler and Pulmicort Respules
Number of Participants With Adverse Events (AEs)50

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pulmicort Turbuhaler and Pulmicort Respules—0/108 (0%)7/105 (6.7%)
Most frequent other events
Most frequent other events
EventPulmicort Turbuhaler and Pulmicort Respules
NasopharyngitisRenal and urinary disorders7/105

Baseline characteristics

Age Continuous
Age Continuous(Years)Pulmicort Turbuhaler and Pulmicort Respules
Mean43.9 ± 13.4
Sex: Female, Male
Sex: Female, Male(Participants)Pulmicort Turbuhaler and Pulmicort Respules
Female73
Male33
08

Study locations

6 sites
  • Research Site
    Ichikawa, Chiba, Japan
  • Research Site
    Yokosuka, Kanagawa, Japan
  • Research Site
    Chiyoda, Tokyo, Japan
  • Research City
    Hino, Tokyo, Japan
  • Research Site
    Setagaya, Tokyo, Japan
  • Research Site
    Tachikawa, Tokyo, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2009
First posted
Mar 5, 2009
Start
Feb 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Results first posted
Mar 11, 2011
Last update
Mar 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00855959
Lead sponsor
AstraZeneca
First posted
Mar 5, 2009
Start date
Feb 2009
Primary completion
Aug 2009
Completion
Aug 2009
Results posted
Mar 11, 2011
Last update
Mar 11, 2011

Study contacts

Lars-Göran Carlsson, MD
study director · AstraZeneca R&D Lund

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion